Equities

Zomedica Corp

Zomedica Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.1312
  • Today's Change0.00 / 0.00%
  • Shares traded20.19k
  • 1 Year change-24.47%
  • Beta1.0563
Data delayed at least 15 minutes, as of Nov 22 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments90115195
Total Receivables, Net2.201.860.77
Total Inventory5.122.752.85
Prepaid expenses2.063.801.84
Other current assets, total------
Total current assets100124200
Property, plant & equipment, net259.172.53
Goodwill, net626443
Intangibles, net554234
Long term investments1041--
Note receivable - long term------
Other long term assets0.820.270.27
Total assets253280280
LIABILITIES
Accounts payable------
Accrued expenses0.980.190.24
Notes payable/short-term debt000
Current portion long-term debt/capital leases--0.640.41
Other current liabilities, total0.380.290.46
Total current liabilities9.037.814.34
Total long term debt01.100.96
Total debt01.741.38
Deferred income tax1.141.253.71
Minority interest------
Other liabilities, total3.012.070.50
Total liabilities13129.51
SHAREHOLDERS EQUITY
Common stock381381381
Additional paid-in capital30249.31
Retained earnings (accumulated deficit)(171)(136)(119)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.05(0.84)0.00
Total equity240267271
Total liabilities & shareholders' equity253280280
Total common shares outstanding980980980
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.